Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for EXEL

Stock Name	Exelixis Inc
Ticker	EXEL(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US30161Q1040

Show aggregate EXEL holdings

News associated with EXEL

Exelixis (NASDAQ:EXEL) Price Target Raised to $50.00 at Morgan Stanley: Exelixis (NASDAQ:EXEL – Get Free Report) had its price objective lifted by investment analysts at Morgan Stanley from $46.00 to $50.00 in a report issued on Wednesday, MarketBeat Ratings reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Morgan Stanley’s price target suggests a potential upside of 23.61% from the company’s […] - 2025-09-19 02:36:46
Exelixis (NASDAQ:EXEL) Rating Increased to Hold at Barclays: Barclays upgraded shares of Exelixis (NASDAQ:EXEL – Free Report) to a hold rating in a research report report published on Tuesday morning,Zacks.com reports. A number of other analysts also recently weighed in on the company. Bank of America lifted their price target on Exelixis from $45.00 to $46.00 and gave the company a “neutral” rating […] - 2025-09-19 02:02:49
Exelixis (NASDAQ:EXEL) Rating Lowered to “Hold” at Wall Street Zen: Exelixis (NASDAQ:EXEL – Get Free Report) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Monday. Several other equities analysts have also recently issued reports on the company. Guggenheim reiterated a “buy” rating and issued a $45.00 price objective on shares of Exelixis in a […] - 2025-09-15 02:06:56
Zacks Research Predicts Exelixis’ Q3 Earnings (NASDAQ:EXEL): Exelixis, Inc. (NASDAQ:EXEL – Free Report) – Research analysts at Zacks Research dropped their Q3 2026 earnings estimates for shares of Exelixis in a research report issued on Wednesday, August 27th. Zacks Research analyst Team now anticipates that the biotechnology company will earn $0.62 per share for the quarter, down from their previous estimate of […] - 2025-09-01 02:44:58
Exelixis, Inc. (NASDAQ:EXEL) Receives Average Recommendation of “Moderate Buy” from Analysts: Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-two ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and thirteen have assigned a buy recommendation to the […] - 2025-08-18 05:10:57
Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by LPL Financial LLC: LPL Financial LLC lifted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 74.5% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 187,097 shares of the biotechnology company’s stock after purchasing an additional 79,885 shares during the period. LPL Financial LLC’s holdings […] - 2025-08-11 05:34:56
Exelixis, Inc. (NASDAQ:EXEL) Position Increased by Natixis Advisors LLC: Natixis Advisors LLC boosted its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 14.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 69,922 shares of the biotechnology company’s stock after purchasing an additional 9,072 shares during the period. […] - 2025-08-08 05:18:54
Wall Street Zen Downgrades Exelixis (NASDAQ:EXEL) to Buy: Exelixis (NASDAQ:EXEL – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday. Several other equities analysts also recently commented on the stock. HC Wainwright upped their price target on shares of Exelixis from $47.00 to $53.00 […] - 2025-08-04 04:27:00
Exelixis (NASDAQ:EXEL) Given “Market Outperform” Rating at JMP Securities: Exelixis (NASDAQ:EXEL – Get Free Report)‘s stock had its “market outperform” rating restated by equities research analysts at JMP Securities in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $50.00 target price on the biotechnology company’s stock. JMP Securities’ price objective would suggest a potential upside of 35.69% […] - 2025-07-31 04:18:47
Noteworthy ETF Outflows: XBI, MRNA, ALNY, EXEL: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $225.3 million dollar outflow -- that's a 4.6% decrease week over week - 2025-07-30 11:49:03
Truist Financial Has Lowered Expectations for Exelixis (NASDAQ:EXEL) Stock Price: Exelixis (NASDAQ:EXEL – Free Report) had its price objective trimmed by Truist Financial from $56.00 to $49.00 in a research report released on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. A number of other research firms have also recently weighed in on EXEL. Benchmark reiterated a “neutral” rating […] - 2025-07-30 06:13:05
Exelixis (NASDAQ:EXEL) Given “Outperform” Rating at William Blair: William Blair restated their outperform rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research note published on Tuesday morning,RTT News reports. Several other analysts also recently commented on EXEL. Wells Fargo & Company reiterated a “market outperform” rating on shares of Exelixis in a research report on Thursday, April 17th. Jefferies Financial […] - 2025-07-30 04:54:52
Exelixis (NASDAQ:EXEL) Given New $45.00 Price Target at Royal Bank Of Canada: Exelixis (NASDAQ:EXEL – Free Report) had its target price cut by Royal Bank Of Canada from $50.00 to $45.00 in a research report report published on Tuesday,Benzinga reports. They currently have a sector perform rating on the biotechnology company’s stock. EXEL has been the subject of several other research reports. Truist Financial boosted their target […] - 2025-07-30 04:54:49
Morgan Stanley Cuts Exelixis (NASDAQ:EXEL) Price Target to $46.00: Exelixis (NASDAQ:EXEL – Free Report) had its target price decreased by Morgan Stanley from $48.00 to $46.00 in a report released on Tuesday morning,Benzinga reports. Morgan Stanley currently has an overweight rating on the biotechnology company’s stock. EXEL has been the subject of several other reports. Stephens upgraded Exelixis from an “equal weight” rating to […] - 2025-07-30 04:20:59
Exelixis Target of Unusually Large Options Trading (NASDAQ:EXEL): Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) was the target of some unusual options trading activity on Tuesday. Stock traders acquired 12,250 call options on the stock. This is an increase of 373% compared to the typical volume of 2,588 call options. Wall Street Analysts Forecast Growth Several brokerages have issued reports on EXEL. Morgan […] - 2025-07-30 03:07:01
Exelixis (NASDAQ:EXEL) Shares Gap Down on Analyst Downgrade: Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s share price gapped down before the market opened on Tuesday after Truist Financial lowered their price target on the stock from $56.00 to $49.00. The stock had previously closed at $44.39, but opened at $38.26. Truist Financial currently has a buy rating on the stock. Exelixis shares last […] - 2025-07-30 03:06:57
Arizona State Retirement System Sells 790 Shares of Exelixis, Inc. (NASDAQ:EXEL): Arizona State Retirement System trimmed its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 1.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 73,696 shares of the biotechnology company’s stock after selling 790 shares during the period. Arizona […] - 2025-07-17 06:56:52
Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Cerity Partners LLC: Cerity Partners LLC boosted its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 127.3% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 167,915 shares of the biotechnology company’s stock after purchasing an additional 94,031 shares during the quarter. Cerity Partners LLC owned […] - 2025-07-16 06:51:24
Exelixis, Inc. (NASDAQ:EXEL) Holdings Reduced by Alps Advisors Inc.: Alps Advisors Inc. decreased its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 25.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,709 shares of the biotechnology company’s stock after selling 3,291 shares during the period. Alps Advisors Inc.’s holdings […] - 2025-07-16 05:23:13
Bank of New York Mellon Corp Grows Position in Exelixis, Inc. (NASDAQ:EXEL): Bank of New York Mellon Corp lifted its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 0.6% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,476,857 shares of the biotechnology company’s stock after purchasing an additional 15,239 shares during the quarter. Bank […] - 2025-07-11 06:13:00
Principal Financial Group Inc. Sells 14,218 Shares of Exelixis, Inc. (NASDAQ:EXEL): Principal Financial Group Inc. lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 2.1% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 648,218 shares of the biotechnology company’s stock after selling 14,218 shares during the period. Principal Financial Group Inc. owned approximately 0.24% […] - 2025-07-09 05:51:35
Traders Buy Large Volume of Call Options on Exelixis (NASDAQ:EXEL): Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) was the recipient of unusually large options trading activity on Monday. Traders purchased 3,495 call options on the stock. This is an increase of 56% compared to the typical daily volume of 2,238 call options. Insider Activity In other Exelixis news, Director Sue Gail Eckhardt sold 18,838 shares […] - 2025-07-09 02:50:45
Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by New York State Teachers Retirement System: New York State Teachers Retirement System cut its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 12.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 359,105 shares of the biotechnology company’s stock after selling 52,707 shares during the period. New York State Teachers Retirement […] - 2025-07-04 05:31:06
HC Wainwright Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) Stock: Exelixis (NASDAQ:EXEL – Get Free Report) had its price objective hoisted by research analysts at HC Wainwright from $47.00 to $53.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 21.50% from […] - 2025-07-02 03:02:56
Bartlett & CO. Wealth Management LLC Makes New $37,000 Investment in Exelixis, Inc. (NASDAQ:EXEL): Bartlett & CO. Wealth Management LLC purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,000 shares of the biotechnology company’s stock, valued at approximately $37,000. A number of other hedge […] - 2025-06-30 06:44:51
Exelixis (NASDAQ:EXEL) Raised to “Overweight” at Stephens: Exelixis (NASDAQ:EXEL – Get Free Report) was upgraded by research analysts at Stephens from an “equal weight” rating to an “overweight” rating in a research note issued on Tuesday, Marketbeat Ratings reports. The firm presently has a $60.00 target price on the biotechnology company’s stock, up from their prior target price of $29.00. Stephens’ price […] - 2025-06-26 02:48:49
Exelixis (NASDAQ:EXEL) Shares Gap Up on Analyst Upgrade: Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s stock price gapped up prior to trading on Monday after Stephens upgraded the stock from an equal weight rating to an overweight rating. The stock had previously closed at $40.37, but opened at $49.43. Stephens now has a $60.00 price target on the stock, up from their previous […] - 2025-06-25 02:18:52
Exelixis (NASDAQ:EXEL) Reaches New 52-Week High After Analyst Upgrade: Shares of Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) reached a new 52-week high during trading on Tuesday after Stephens upgraded the stock from an equal weight rating to an overweight rating. Stephens now has a $60.00 price target on the stock, up from their previous price target of $29.00. Exelixis traded as high as […] - 2025-06-25 02:18:49
Blue Trust Inc. Increases Holdings in Exelixis, Inc. (NASDAQ:EXEL): Blue Trust Inc. increased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 15.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 12,976 shares of the biotechnology company’s stock after purchasing an additional 1,745 shares during the period. […] - 2025-06-22 05:22:52
Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by Farther Finance Advisors LLC: Farther Finance Advisors LLC increased its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 6.1% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,372 shares of the biotechnology company’s stock after acquiring an additional 307 shares during the quarter. Farther Finance Advisors […] - 2025-06-20 04:26:51

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) EXEL holdings

Date	Number of EXEL Shares Held	Base Market Value of EXEL Shares	Local Market Value of EXEL Shares	Change in EXEL Shares Held	Change in EXEL Base Value	Current Price per EXEL Share Held	Previous Price per EXEL Share Held
2025-11-11 (Tuesday)	174,072	USD 7,480,744	USD 7,480,744	0	USD 272,422	USD 42.975	USD 41.41
2025-11-10 (Monday)	174,072	USD 7,208,322	USD 7,208,322	445	USD 122,604	USD 41.41	USD 40.81
2025-11-07 (Friday)	173,627	USD 7,085,718	USD 7,085,718	0	USD 1,736	USD 40.81	USD 40.8
2025-11-06 (Thursday)	173,627	USD 7,083,982	USD 7,083,982	445	USD 92,625	USD 40.8	USD 40.37
2025-11-05 (Wednesday)	173,182	USD 6,991,357	USD 6,991,357	0	USD 427,759	USD 40.37	USD 37.9
2025-11-04 (Tuesday)	173,182	USD 6,563,598	USD 6,563,598	447	USD -10,696	USD 37.9	USD 38.06
2025-11-03 (Monday)	172,735	USD 6,574,294	USD 6,574,294	0	USD -105,368	USD 38.06	USD 38.67
2025-10-31 (Friday)	172,735	USD 6,679,662	USD 6,679,662	0	USD -46,639	USD 38.67	USD 38.94
2025-10-30 (Thursday)	172,735	USD 6,726,301	USD 6,726,301	2,235	USD 3,486	USD 38.94	USD 39.43
2025-10-29 (Wednesday)	170,500	USD 6,722,815	USD 6,722,815	894	USD -74,145	USD 39.43	USD 40.075
2025-10-28 (Tuesday)	169,606	USD 6,796,960	USD 6,796,960	0	USD 14,416	USD 40.075	USD 39.99
2025-10-27 (Monday)	169,606	USD 6,782,544	USD 6,782,544	0	USD 215,400	USD 39.99	USD 38.72

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of EXEL by Blackrock for IE00BDZVHG35

Show aggregate share trades of EXEL

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 BUY 445 41.540 39.850 40.019 USD 17,808 37.92
2025-11-06 BUY 445 41.213 40.050 40.166 USD 17,874 37.89
2025-11-04 BUY 447 38.900 37.582 37.714 USD 16,858 37.88
2025-10-30 BUY 2,235 39.755 38.920 39.003 USD 87,173 37.87
2025-10-29 BUY 894 39.430 40.240 40.159 USD 35,902 37.86
2025-10-22 SELL -1,788 36.080 36.450 36.413 USD -65,106 37.84 Profit of 2,552 on sale
2025-10-20 BUY 894 34.540 36.170 36.007 USD 32,190 37.87
2025-10-17 BUY 2,233 39.250 39.600 39.565 USD 88,349 37.86
2025-10-15 BUY 3,560 40.030 40.540 40.489 USD 144,141 37.85
2025-10-03 BUY 3,101 40.090 41.450 41.314 USD 128,115 37.83
2025-10-02 BUY 443 41.350 41.400 41.395 USD 18,338 37.80
2025-09-30 BUY 886 41.300 41.600 41.570 USD 36,831 37.76
2025-09-26 BUY 886 39.040 39.240 39.220 USD 34,749 37.74
2025-09-25 BUY 886 38.690 38.910 38.888 USD 34,455 37.73
2025-09-18 BUY 469 40.450 40.590 40.576 USD 19,030 37.72
2025-09-17 BUY 1,413 40.440 40.780 40.746 USD 57,574 37.70
2025-09-11 SELL -471 39.070 39.090 39.088 USD -18,410 37.68 Loss of -662 on sale
2025-09-10 BUY 942 37.700 38.500 38.420 USD 36,192 37.68
2025-07-17 SELL -942 44.870 45.520 45.455 USD -42,819 37.55 Loss of -7,451 on sale
2025-07-16 BUY 1,460 44.810 44.850 44.846 USD 65,475 37.50
2025-07-11 SELL -3,736 44.860 45.410 45.355 USD -169,446 37.35 Loss of -29,897 on sale
2025-07-02 BUY 25,685 44.300 44.430 44.417 USD 1,140,851 37.15
2025-06-25 BUY 934 43.530 45.720 45.501 USD 42,498 36.97
2025-06-20 BUY 640 40.370 41.030 40.964 USD 26,217 36.83
2025-06-11 BUY 930 41.430 42.650 42.528 USD 39,551 36.60
2025-06-10 BUY 930 42.520 43.500 43.402 USD 40,364 36.55
2025-06-04 SELL -465 42.220 43.110 43.021 USD -20,005 36.36 Loss of -3,097 on sale
2025-04-23 BUY 465 36.780 37.670 37.581 USD 17,475 35.05
2025-04-10 SELL -3,720 34.460 34.900 34.856 USD -129,664 34.97 Profit of 413 on sale
2025-04-08 SELL -465 34.130 35.860 35.687 USD -16,594 34.97 Loss of -332 on sale
2025-04-07 SELL -465 34.840 35.250 35.209 USD -16,372 34.97 Loss of -109 on sale
2025-04-04 SELL -2,325 34.570 36.450 36.262 USD -84,309 34.98 Loss of -2,984 on sale
2025-04-01 BUY 4,029 36.390 37.180 37.101 USD 149,480 34.94
2025-03-31 SELL -1,374 36.920 37.120 37.100 USD -50,975 34.91 Loss of -3,006 on sale
2025-03-21 BUY 2,619 36.960 37.990 37.887 USD 99,226 34.74
2025-03-14 SELL -7,184 36.650 37.380 37.307 USD -268,013 34.59 Loss of -19,547 on sale
2025-03-07 SELL -898 38.580 39.000 38.958 USD -34,984 34.35 Loss of -4,140 on sale
2025-03-04 SELL -449 38.290 38.950 38.884 USD -17,459 34.16 Loss of -2,123 on sale
2025-02-25 BUY 898 36.920 37.570 37.505 USD 33,679 33.84
2025-02-19 SELL -449 35.070 35.460 35.421 USD -15,904 33.67 Loss of -785 on sale
2025-02-13 BUY 1,347 34.490 34.600 34.589 USD 46,591 33.59
2025-02-12 BUY 449 32.800 35.370 35.113 USD 15,766 33.61
2025-02-11 BUY 1,796 32.810 33.610 33.530 USD 60,220 33.63
2025-01-02 BUY 710 33.940 33.970 33.967 USD 24,117 33.79
2024-12-30 SELL -15,662 33.700 34.150 34.105 USD -534,153 33.80 Loss of -4,824 on sale
2024-11-18 SELL -7,335 34.520 34.630 34.619 USD -253,930 31.95 Loss of -19,554 on sale
2024-11-08 SELL -489 36.250 36.600 36.565 USD -17,880 31.37 Loss of -2,541 on sale
2024-10-21 SELL -490 28.660 29.090 29.047 USD -14,233 0.00 Loss of -14,233 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	BUY	445	41.540	39.850	40.019	USD 17,808	37.92
2025-11-06	BUY	445	41.213	40.050	40.166	USD 17,874	37.89
2025-11-04	BUY	447	38.900	37.582	37.714	USD 16,858	37.88
2025-10-30	BUY	2,235	39.755	38.920	39.003	USD 87,173	37.87
2025-10-29	BUY	894	39.430	40.240	40.159	USD 35,902	37.86
2025-10-22	SELL	-1,788	36.080	36.450	36.413	USD -65,106	37.84 Profit of 2,552 on sale
2025-10-20	BUY	894	34.540	36.170	36.007	USD 32,190	37.87
2025-10-17	BUY	2,233	39.250	39.600	39.565	USD 88,349	37.86
2025-10-15	BUY	3,560	40.030	40.540	40.489	USD 144,141	37.85
2025-10-03	BUY	3,101	40.090	41.450	41.314	USD 128,115	37.83
2025-10-02	BUY	443	41.350	41.400	41.395	USD 18,338	37.80
2025-09-30	BUY	886	41.300	41.600	41.570	USD 36,831	37.76
2025-09-26	BUY	886	39.040	39.240	39.220	USD 34,749	37.74
2025-09-25	BUY	886	38.690	38.910	38.888	USD 34,455	37.73
2025-09-18	BUY	469	40.450	40.590	40.576	USD 19,030	37.72
2025-09-17	BUY	1,413	40.440	40.780	40.746	USD 57,574	37.70
2025-09-11	SELL	-471	39.070	39.090	39.088	USD -18,410	37.68 Loss of -662 on sale
2025-09-10	BUY	942	37.700	38.500	38.420	USD 36,192	37.68
2025-07-17	SELL	-942	44.870	45.520	45.455	USD -42,819	37.55 Loss of -7,451 on sale
2025-07-16	BUY	1,460	44.810	44.850	44.846	USD 65,475	37.50
2025-07-11	SELL	-3,736	44.860	45.410	45.355	USD -169,446	37.35 Loss of -29,897 on sale
2025-07-02	BUY	25,685	44.300	44.430	44.417	USD 1,140,851	37.15
2025-06-25	BUY	934	43.530	45.720	45.501	USD 42,498	36.97
2025-06-20	BUY	640	40.370	41.030	40.964	USD 26,217	36.83
2025-06-11	BUY	930	41.430	42.650	42.528	USD 39,551	36.60
2025-06-10	BUY	930	42.520	43.500	43.402	USD 40,364	36.55
2025-06-04	SELL	-465	42.220	43.110	43.021	USD -20,005	36.36 Loss of -3,097 on sale
2025-04-23	BUY	465	36.780	37.670	37.581	USD 17,475	35.05
2025-04-10	SELL	-3,720	34.460	34.900	34.856	USD -129,664	34.97 Profit of 413 on sale
2025-04-08	SELL	-465	34.130	35.860	35.687	USD -16,594	34.97 Loss of -332 on sale
2025-04-07	SELL	-465	34.840	35.250	35.209	USD -16,372	34.97 Loss of -109 on sale
2025-04-04	SELL	-2,325	34.570	36.450	36.262	USD -84,309	34.98 Loss of -2,984 on sale
2025-04-01	BUY	4,029	36.390	37.180	37.101	USD 149,480	34.94
2025-03-31	SELL	-1,374	36.920	37.120	37.100	USD -50,975	34.91 Loss of -3,006 on sale
2025-03-21	BUY	2,619	36.960	37.990	37.887	USD 99,226	34.74
2025-03-14	SELL	-7,184	36.650	37.380	37.307	USD -268,013	34.59 Loss of -19,547 on sale
2025-03-07	SELL	-898	38.580	39.000	38.958	USD -34,984	34.35 Loss of -4,140 on sale
2025-03-04	SELL	-449	38.290	38.950	38.884	USD -17,459	34.16 Loss of -2,123 on sale
2025-02-25	BUY	898	36.920	37.570	37.505	USD 33,679	33.84
2025-02-19	SELL	-449	35.070	35.460	35.421	USD -15,904	33.67 Loss of -785 on sale
2025-02-13	BUY	1,347	34.490	34.600	34.589	USD 46,591	33.59
2025-02-12	BUY	449	32.800	35.370	35.113	USD 15,766	33.61
2025-02-11	BUY	1,796	32.810	33.610	33.530	USD 60,220	33.63
2025-01-02	BUY	710	33.940	33.970	33.967	USD 24,117	33.79
2024-12-30	SELL	-15,662	33.700	34.150	34.105	USD -534,153	33.80 Loss of -4,824 on sale
2024-11-18	SELL	-7,335	34.520	34.630	34.619	USD -253,930	31.95 Loss of -19,554 on sale
2024-11-08	SELL	-489	36.250	36.600	36.565	USD -17,880	31.37 Loss of -2,541 on sale
2024-10-21	SELL	-490	28.660	29.090	29.047	USD -14,233	0.00 Loss of -14,233 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of EXEL

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	349,384	0	595,253	58.7%
2025-09-18	430,450	11,761	708,167	60.8%
2025-09-17	504,083	1,036	836,321	60.3%
2025-09-16	404,430	0	563,875	71.7%
2025-09-15	329,606	441	529,065	62.3%
2025-09-12	524,842	4,207	913,692	57.4%
2025-09-11	562,177	3,134	902,871	62.3%
2025-09-10	572,567	3,800	905,184	63.3%
2025-09-09	397,859	8,844	684,471	58.1%
2025-09-08	313,702	25	519,022	60.4%
2025-09-05	559,014	1,313	808,217	69.2%
2025-09-04	422,907	6,992	675,247	62.6%
2025-09-03	599,362	2,245	1,023,151	58.6%
2025-09-02	1,012,249	954	1,595,650	63.4%
2025-08-29	501,443	2,883	758,573	66.1%
2025-08-28	476,124	1,667	704,826	67.6%
2025-08-27	441,436	666	588,517	75.0%
2025-08-26	399,893	1,239	562,757	71.1%
2025-08-25	355,644	31	551,409	64.5%
2025-08-22	308,605	540	468,551	65.9%
2025-08-21	589,902	0	745,828	79.1%
2025-08-20	385,633	314	503,585	76.6%
2025-08-19	433,048	813	690,899	62.7%
2025-08-18	468,009	321	691,081	67.7%
2025-08-15	387,499	29,516	649,336	59.7%
2025-08-14	510,428	160	775,522	65.8%
2025-08-13	508,860	520	720,588	70.6%
2025-08-12	564,759	583	792,782	71.2%
2025-08-11	531,570	150	830,838	64.0%
2025-08-08	501,446	198	911,580	55.0%
2025-08-07	716,346	129	1,140,877	62.8%
2025-08-06	568,916	378	881,700	64.5%
2025-08-05	682,745	15,446	1,418,128	48.1%
2025-08-04	976,230	24	1,600,059	61.0%
2025-08-01	1,884,490	117	2,637,563	71.4%
2025-07-31	1,209,024	2,215	1,711,147	70.7%
2025-07-30	912,071	37,267	1,899,827	48.0%
2025-07-29	4,273,219	106,296	7,518,518	56.8%
2025-07-28	1,728,119	875	2,115,607	81.7%
2025-07-25	843,185	401	1,143,922	73.7%
2025-07-24	436,484	322	684,873	63.7%
2025-07-23	587,574	1,065	808,716	72.7%
2025-07-22	495,903	110	758,132	65.4%
2025-07-21	417,849	0	569,349	73.4%
2025-07-18	376,445	1	509,088	73.9%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE